Journal article · 2026 · Open access

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial

DANIEL JOHN GREEN, Andrew Haynes, Destiny R Underwood, Evangeline R. Winterton, Abbey A Green, Robin M. Daly, Elena George, Leanne Lester, Louise H. Naylor, Graham S. Hillis, P. Gerry Fegan, Bu Beng Yeap

Nature Medicine · Published 9 November 2026 · DOI 10.1038/s41591-026-04752-5

Open PDFView at the publisherCite this paper

In brief

“Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial” is a 2026 journal article by DANIEL JOHN GREEN and 11 co-authors, published in Nature Medicine. OpenAlex counts 1 citations as of 18 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.23
References
49
Authors
12

Abstract

Incretin mimetics as obesity therapy induce substantial weight and fat loss but also decrease lean soft tissue mass, possibly impairing skeletal muscle function. Here, in this two-arm randomized controlled trial of adding resistance exercise (REx) to tirzepatide (T), 120 adults with overweight or obesity were treated with tirzepatide and randomized to thrice-weekly resistance exercise training or usual activities for 40 weeks. Tirzepatide was safe, and most participants tolerated up-titration to 15 mg weekly. Adherence to resistance exercise was 91%. Weight loss achieved was similar (T = -22.61 kg, T+REx = -22.28 kg, P = 0.694). For primary outcomes, loss of total fat mass was similar (T = -17.19 kg, T+REx = -17.98 kg, P = 0.700; between-group difference = -0.77 kg, 95% confidence interval (CI): -2.14 kg to 0.60 kg), but resistance exercise reduced loss of total lean soft tissue mass (T = -4.67 kg, T+REx = -3.57 kg, P < 0.001; between-group difference = 1.09 kg, 95% CI: 0.43-1.75 kg). For related endpoints, resistance exercise reduced loss of appendicular lean soft tissue mass (T = -3.55 kg, T+REx = -2.92 kg, P < 0.001). Upper and lower body muscle strength decreased with tirzepatide (bench press -4.09 kg, lat pulldown -4.42 kg, knee extension -4.42 kg) but increased with T+REx (+4.68 kg, +8.58 kg, +5.88 kg, respectively, all P < 0.001 versus tirzepatide). In conclusion, resistance exercise training attenuated loss of total lean soft tissue mass, representing an effective adjunct to tirzepatide anti-obesity therapy. Australian New Zealand Clinical Trials Registry identifier: ACTRN12623001236684 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

GREEN, D. J., Haynes, A., Underwood, D. R., Winterton, E. R., Green, A. A., Daly, R. M., George, E., Lester, L., Naylor, L. H., Hillis, G. S., Fegan, P. G., & Yeap, B. B. (2026). Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04752-5

MLA 9

GREEN, DANIEL JOHN, et al. “Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04752-5.

Chicago

GREEN, DANIEL JOHN, Andrew Haynes, Destiny R Underwood, Evangeline R. Winterton, Abbey A Green, Robin M. Daly, Elena George, et al. 2026. “Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.” Nature Medicine. https://doi.org/10.1038/s41591-026-04752-5.

Harvard

GREEN, D. J. et al. (2026) ‘Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial’, Nature Medicine. doi:10.1038/s41591-026-04752-5.

IEEE

D. J. GREEN et al., “Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04752-5.

BibTeX

@article{green2026resistance,
  title     = {{Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial}},
  author    = {GREEN, DANIEL JOHN and Haynes, Andrew and Underwood, Destiny R and Winterton, Evangeline R. and Green, Abbey A and Daly, Robin M. and George, Elena and Lester, Leanne and Naylor, Louise H. and Hillis, Graham S. and Fegan, P. Gerry and Yeap, Bu Beng},
  journal   = {Nature Medicine},
  year      = {2026},
  doi       = {10.1038/s41591-026-04752-5},
  url       = {https://doi.org/10.1038/s41591-026-04752-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment

  • resistance training
  • tirzepatide
  • obesity
  • lean mass loss
  • fat loss
  • weight loss
  • muscle strength
  • skeletal muscle function

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

GREEN, D. J., Haynes, A., Underwood, D. R., Winterton, E. R., Green, A. A., Daly, R. M., George, E., Lester, L., Naylor, L. H., Hillis, G. S., Fegan, P. G., & Yeap, B. B. (2026). Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04752-5

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

DANIEL JOHN GREEN, Andrew Haynes, Destiny R Underwood, Evangeline R. Winterton, Abbey A Green, Robin M. Daly, Elena George, Leanne Lester, Louise H. Naylor, Graham S. Hillis, P. Gerry Fegan, Bu Beng Yeap.

What is the DOI of this paper?

10.1038/s41591-026-04752-5, permanently at https://doi.org/10.1038/s41591-026-04752-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.